Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Borgen on the Decision to be Tested for a BRCA Gene

May 23rd 2013

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses a patient's decision to be tested for a BRCA gene.

Dr. Morris on rPFS as an Endpoint in Clinical Trials

May 22nd 2013

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of radiographic progression-free survival as an endpoint in prostate cancer clinical trials.

Chip Petricoin on the Discovery of New Biomarkers

May 20th 2013

Emanuel F. "Chip" Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.

A National Dialogue on Genetic Testing for Breast Cancer

May 16th 2013

A high-profile case of a medical decision being based primarily on the results of a genetic test has prompted a national discussion on the benefits and risks associated with acting on the results of such a test.

FDA Approves Frontline Erlotinib With Novel Companion Diagnostic for Advanced NSCLC

May 14th 2013

The FDA concurrently approved erlotinib along with a companion diagnostic to be used together in the first-line treatment of patients with metastatic non-small cell lung cancer harboring a specific EGFR mutation.

Cancer Treatment-It's Personal Now

May 10th 2013

The majority of the new oncology drugs approved in 2012 are oral agents, and by reviewing the indications for these agents, it's easy to see how genetics impacts the agent's efficacy.

Counseling BRCA, Lynch Carriers on Prophylactic Oophorectomy

May 8th 2013

Due to the high lifetime risk of ovarian cancer and the poor ovarian cancer surveillance options available, women who carry BRCA1 or BRCA2 mutations are advised to remove their ovaries and fallopian tubes by age 40 or when childbearing is complete.

Dr. Camidge on Targeted Therapies in Adjuvant NSCLC

May 7th 2013

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the selective administration of targeted therapies in the adjuvant setting for patients with non-small cell lung cancer.

Herbert Irving Comprehensive Cancer Center Joins OncLive's Strategic Alliance Partnership

May 7th 2013

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program.

AACR President Frank McCormick, PhD, Reflects on Past Progress and Looks to the Future

May 6th 2013

An interesting conversation with this year's AACR president, Frank McCormick, PhD, on the next big area of interest in cancer research, and what the future holds for cancer research progress.

Dr. Tripathy Reviews Targeted Therapies in Breast Cancer

May 3rd 2013

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the targeted therapies that are currently available for the treatment of patients with breast cancer.

Serendipity in Science: NSCLC Specialist Matches Therapies With Targets

May 3rd 2013

An interview with Alice Tsang Shaw, MD, PhD, who has won broad recognition for her contributions to the treatment of NSCLC, including the use of crizotinib to target the ROS1 gene rearrangement and research into other emerging agents.

Dr. Carey on the Future of Clinical Trial Design

May 2nd 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the present and future state of clinical trial design.

Worldwide Effort Yields Major Advances in Identifying Genetic Risks for Breast, Prostate, and Ovarian Cancer

April 30th 2013

A large, international study has yielded a wealth of new information about genetic alterations that can increase an individual's risk of breast, prostate, and ovarian cancer.

Wide Variation Found in EGFR Testing Patterns

April 29th 2013

A study of patients newly initiated to erlotinib therapy for NSCLC found that there is no uniformity in the billing codes used for pharmacogenomic testing prior to starting the drug, making it difficult to analyze treatment patterns and cost impact.

USC Works With "Dream Team" to Deliver Promise of Epigenetic Therapy to Clinical Practice

April 29th 2013

Barbara J. Gitlitz, MD, Stephen V. Liu, MD, and Peter A. Jones, PhD, DSc, from the USC Norris Comprehensive Cancer Center, describe efforts to translate promising epigenetic research into clinical practice.

Dutch Researcher Focuses on Fc Signaling in Targeting CD20

April 25th 2013

Jeanette H.W. Leusen, PhD, focuses on studying the working mechanisms of therapeutic antibodies and the biology of fragment crystallizable receptors, including the anti-CD20 monoclonal antibody rituximab in patients with non-Hodgkin lymphoma.

Targeting CD20: Rituximab's Success Fuels Interest in New Agents

April 25th 2013

A large proportion of patients become rituximab-refractory, which has prompted the development of newer CD20 agents with altered structures that are designed to improve upon rituximab's performance.

Dr. Caudle on Upcoming Breast Cancer Trial Results

April 24th 2013

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.

Dr. Andre Discusses Testing for Genomic Alterations

April 22nd 2013

Fabrice Andre, MD, PhD, from the Institut Gustave Roussy, Villejuif, France, gives an overview of methods for improving the effectiveness of genomic alteration testing in clinical trials that explore novel targeted agents in breast cancer.

NEXT PAGE
PREVIOUS PAGE